Skip to main content
. 2018 Nov 16;10:139–152. doi: 10.2147/HMER.S180246

Table 3.

Concomitant therapies

Variables ELAD
Control
P-valuea
n/N Percentage n/N Percentage

Patients receiving therapies
Any concomitant therapy 15/32 46.9 6/17 35.3 0.549
Plasma exchange 11/32 34.4 5/17 29.4 1.000
Plasma bilirubin absorption 5/32 15.6 3/17 17.6 1.000
Continuous blood filtration 3/32 9.4 1/17 5.9 1.000

Note:

a

P-values determined using Fisher’s exact test.